A pre-IND package is summarized as a long mixed list. Governance needs to know whether the asset is ready, blocked, or ready with constraints. IND evidence table: biology -> nonclinical safety -> CMC -> clinical protocol The common trap is counting completed bullets instead of checking whether each evidence lane supports the human-testing plan. Step 1 Separate every bullet by evidence lane: biology, nonclinical, CMC, or clinical protocol. A target-engagement assay cannot close a stability gap, and a clean tox study cannot validate a release assay. Sorting prevents lane substitution. Step 2 For each lane, write the decision it supports:…
Read the full lesson
Sign up free: one personalized lesson every day, matched to your role and goals.
Already have an account? Sign in